Outlook Therapeutics, Inc.
Price
Where the revenue goes
Loading the income statement flow…
Where the revenue comes from
Fundamentals
Loading key figures…
Insiders, analysts and people
All trades and changesLoading insiders, analysts and opinions…
Co se právě děje
AI souhrnAbout the company
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
- Website
- outlooktherapeutics.com
- Employees
- 17
- Country
- United States
- Fiscal year end
- 30. 9.
- Data since
- 14. 6. 2016
Explore further
Similar companies VTVT